CpG DNA and immunotherapy of allergic airway diseases

Clinical and Experimental Allergy

Volumn 33, Issue 10, 2003, Pages 1330-1335

  Jain, V V ^a   Kitagaki, K ^a   Kline, J N ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b Division of Pulmonary   (United States)

Author keywords

Asthma; Atopic; Bacterial DNA; Cytokine; Immunotherapy; T regulatory; Vaccine

Indexed keywords

ALLERGEN; BACTERIAL DNA; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 5; OLIGONUCLEOTIDE;

ALLERGY; ASTHMA; EOSINOPHILIA; GOBLET CELL; HISTOPATHOLOGY; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RURAL POPULATION; TH1 CELL;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; HUMANS; IMMUNOTHERAPY; MICE; OLIGODEOXYRIBONUCLEOTIDES;

EID: 0142042447     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.2003.01763.x     Document Type: Review

References (48)

1. Kline JN, Kitagaki K, Businga TR, Jain VV. Treatment of established asthma in a murine model using CpG oligonucleotides. Am J Physiol Lung Cell Mol Physiol 2002; 283:L170-9.
2. Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555-9.
3. Hussain I, Jain VV, Kitagaki K, Businga TR, O'Shaughnessy P, Kline JN. Modulation of murine allergic rhinosinusitis by CpG oligodeoxynucleotides. Laryngoscope 2002; 112:1819-26.
4. Jain VV, Kitagaki K, Businga T et al. CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma. J Allergy Clin Immunol 2002; 110:867-72.
5. Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? a meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 1995; 151:969-74.
6. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2000; 2.
7. Krieg AM. Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol 1996; 4:73-6.
8. Hemmi H, Takeuchi O, Kawai T et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-5.
9. Krieg AM. A role for Toll in autoimmunity. Nat Immunol 2002; 3:423-4.
10. Takeshita F, Leifer CA, Gursel I et al. Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 2001; 167:3555-8.
11. + T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 1994; 10:587-93.
12. Brusselle G, Kips J, Joos G, Bluethmann H, Pauwels R. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 1995; 12:254-9.
13. Foster PS, Hogan SP, Ramsay AJ, Matthaei KI, Young IG. Interleukin 5 deficiency abolishes eosinophilia, airway hyperreactivity and lung damage in a mouse asthma model. J Exp Med 1996; 183:195-201.
14. Lefort J, Bachelet CM, Leduc D, Vargaftig BB. Effect of antigen provocation of IL-5 transgenic mice on eosinophil mobilization and bronchial hyperresponsiveness. J Allergy Clin Immunol 1996; 97:788-99.
15. Rankin JA, Picarella DE, Geba GP et al. Phenotypic and physiologic characterization of transgenic mice expressing interleukin 4 in the lung: lymphocytic and eosinophilic inflammation without airway hyperreactivity. Proc Natl Acad Sci USA 1996; 93:7821-5.
16. Corry DB, Folkesson HG, Warnock ML et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183: 109-17.
17. Coyle AJ, Le Gros G, Bertrand C et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am J Respir Cell Mol Biol 1995; 13:54-9.
18. Mathur M, Herrmann K, Li X et al. TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med 1999; 159:580-7.
19. Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 2000; 356:2144-8.
20. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR. CpG oligodeoxynucleotides do not require Th1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999; 104: 1258-64.
21. Broide D, Schwarze J, Tighe H et al. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol 1998; 161:7054-62.
22. Sur S, Wild JS, Choudhury BK, Sur N, Alam R, Klinman DM. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides. J Immunol 1999; 162:6284-93.
23. Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282:2258-61.
24. Kuperman DA, Huang X, Koth LL et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med 2002; 8: 885-9.
25. Walter DM, McIntire JJ, Berry G et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001; 167:4668-75.
26. Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol 1998; 161:3813-6.
27. Kibe A, Inoue H, Fukuyama S et al. Differential regulation by glucocorticoid of interleukin-13-induced eosinophilia, hyperresponsiveness, and goblet cell hyperplasia in mouse airways. Am J Respir Crit Care Med 2003; 167:50-6.
28. Taube C, Duez C, Cui ZH et al. The role of IL-13 in established allergic airway disease. J Immunol 2002; 169:6482-9.
29. Serebrisky D, Teper AA, Huang CK et al. CpG oligodeoxynucleotides can reverse Th2-associated allergic airway responses and alter the B7.1/B7.2 expression in a murine model of asthma. J Immunol 2000; 165:5906-12.
30. Kuribayashi K, Kodama T, Okamura H, Sugita M, Matsuyama T. Effects of post-inhalation treatment with interleukin-12 on airway hyper-reactivity, eosinophilia and interleukin-18 receptor expression in a mouse model of asthma. Clin Exp Allergy 2002; 32:641-9.
31. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995; 270:908.
32. Bryan SA, O'Connor BJ, Matti S et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356:2149-53.
33. Kline JN, Krieg AM, Waldschmidt TJ, Ballas ZK, Jain V, Businga TR. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. J Allergy Clin Immunol 1999; 104:1258-64.
34. Kitagaki K, Jain V, Businga T, Hussain I, Kline J. Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin Diag Lab Immunol 2002; 9:1260-9.
35. Kline JN, Waldschmidt TJ, Businga TR et al. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol 1998; 160:2555-9.
36. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs. Am J Respir Cell Mol Biol 2000; 22:176-82.
37. Shirota H, Sano K, Kikuchi T, Tamura G, Shirato K. Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immuno-modulator. J Immunol 2000; 164:5575-82.
38. Kulig M, Bergmann R, Tacke U, Wahn U, Guggenmoos-Holzmann I. Long-lasting sensitization to food during the first two years precedes allergic airway disease. The MAS Study Group, Germany. Pediatr Allergy Immunol 1998; 9:61-7.
39. Blyth DI, Pedrick MS, Savage TJ, Hessel EM, Fattah D. Lung inflammation and epithelial changes in a murine model of atopic asthma. Am J Respir Cell Mol Biol 1996; 14: 425-38.
40. Tomkinson A, Cieslewicz G, Duez C, Larson KA, Lee JJ, Gelfand EW. Temporal association between airway hyperresponsiveness and airway eosinophilia in ovalbumin-sensitized mice. Am J Respir Crit Care Med 2001; 163:721-30.
41. Santeliz JV, Van Nest G, Traquina P, Larsen E, Wills-Karp M. Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J Allergy Clin Immunol 2002; 109:455-62.
42. Wilson JW, Li X, Pain MC. The lack of distensibility of asthmatic airways. Am Rev Respir Dis 1993; 148:806-9.
43. James AL, Pare PD, Hogg JC. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 1989; 139:242-6.
44. Warshamana GS, Martinez S, Lasky JA, Corti M, Brody AR. Dexamethasone activates expression of the PDGF-alpha receptor and induces lung fibroblast proliferation. Am J Physiol 1998; 274:L499-507.
45. Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest 1999; 103:779-88.
46. Suto A, Nakajima H, Kagami SI, Suzuki K, Saito Y, Iwamoto I. Role of CD4(+) CD25(+) regulatory T cells in T helper 2 cell-mediated allergic inflammation in the airways. Am J Respir Crit Care Med 2001; 164:680-7.
47. Cottrez F, Hurst SD, Coffman RL, Groux H. T regulatory cells 1 inhibit a Th2-specific response in vivo. J Immunol 2000; 165: 4848-53.
48. Krieg AM. From A to Z on CpG. Trends Immunol 2002; 23:64-5.